Syncona Ltd (LSE:SYNC)

£ 1.106 0.004 (0.36%) Market Cap: 719.38 Mil Enterprise Value: 719.36 Mil PE Ratio: 0 PB Ratio: 0.63 GF Score: 38/100

Half Year 2024 Syncona Ltd Earnings Call Transcript
Nov 16, 2023

£1.29 (-4.15%)

Earnings
Full Year 2023 Syncona Ltd Earnings Call Transcript
Jun 15, 2023

£1.51 (-2.46%)

Earnings
Half Year 2023 Syncona Ltd Earnings Call Transcript
Nov 17, 2022

£1.78 (+3.01%)

Earnings
Syncona Ltd to Acquire Applied Genetic Technologies Corp Call Transcript
Oct 24, 2022
Full Year 2022 Syncona Ltd Earnings Call Transcript
Jun 16, 2022

£1.91 (+0.32%)

Earnings
Half Year 2022 Syncona Ltd Earnings Call Transcript
Nov 11, 2021

£2.04 (-0.73%)

Earnings
Full Year 2021 Syncona Ltd Earnings Call Transcript
Jun 17, 2021

£2.15

Earnings
Half Year 2021 Syncona Ltd Earnings Call Transcript
Nov 19, 2020

£2.6 (-2.62%)

Earnings
Full Year 2020 Syncona Ltd Earnings Call Transcript
Jun 11, 2020

£2.22 (-0.67%)

Earnings
Full Year 2020 Syncona Ltd Earnings Call - Q&A Session Transcript
Jun 11, 2020

£2.22 (-0.67%)

Earnings
Syncona Ltd Corporate Analyst Meeting Transcript
Feb 04, 2020
Half Year 2020 Syncona Ltd Earnings Call Transcript
Nov 21, 2019

£2.21 (-1.56%)

Earnings

Half Year 2022 Syncona Ltd Earnings Call Transcript

Nov 11, 2021 / 09:00AM GMT

Release Date Price: £2.04 (-0.73%)

Transcript

Operator

Good day, ladies and gentlemen, and welcome to Syncona's Interim Results 2021-'22. (Operator Instructions) I would like to advise all participants that this call is being recorded. I will now hand over to CEO of Syncona, Martin Murphy, to open the presentation. Please go ahead.

Martin Patrick Murphy

Syncona Limited - CEO

Good morning, and welcome to Syncona's interim results. This has been a busy period for us, and we are pleased with the progress across the portfolio, and in particular, the increasing maturation of that portfolio. We've made strong clinical progress. And particularly, we now have 5 companies at the clinical stage, and we've had 7 clinical readouts this year from Autolus, Gyroscope, Freeline and Achilles. Quell and SwanBio continue to make strong progress, and we would expect Quell to be in the clinic early next year, having recently received the approval of their CTA.

On the new investment side, we've made an exciting new investment in a company called Clade Therapeutics, and we'll look forward to talking to you through that later in

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.